Tranexamic Acid, as an Adjunct to Oxytocin Prophylaxis, in the Prevention of Postpartum Hemorrhage in Women Undergoing Elective Cesarean Section: A Single-Center Double-Blind Randomized Controlled Trial

(BJOG. 2023;130(9):1007–1015) Postpartum hemorrhage (PPH) is the main cause of maternal morbidity and mortality worldwide. The World Health Organization (WHO) recommends administration of uterotonics including oxytocin to prevent PPH, but uterotonics alone may not fully prevent PPH from other causes. The World Maternal Antifibrinolytic Trial (WOMAN Trial) reported that tranexamic acid (TXA) reduced PPH-related mortality in PPH cases, and as a result the WHO has included the administration of TXA into their recommendations for PPH treatment. There is speculation about the potential role of prophylactic TXA in preventing PPH.